CG Oncology reports 75.5% complete response rate in Phase 3 bladder cancer trial; median DOR >28 months

CG Oncology, Inc.

83 of 110 patients (75.5%) achieved complete response at any time in BOND-003 for BCG-unresponsive NMIBC with CIS.
Median duration of response not reached but exceeds 28 months; 46% in CR at 12 months.
No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all expected treatments.
Translational data show no systemic exposure, eliminating need for close contact precautions post-treatment.
Data presented as late-breaking abstract at 40th Annual EAU Congress in Madrid.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-043497
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2025-03-24T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.725413+00:00
generated_at: 2026-05-24T07:01:23.509020+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-043497
json_url: https://secwatch.observer/filing/0000950170-25-043497.json
markdown_url: https://secwatch.observer/filing/0000950170-25-043497.md
text_url: https://secwatch.observer/filing/0000950170-25-043497.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/0000950170-25-043497-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/ck0001991792-20250324.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-043497

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.